---
title: "BioTelemetry -> Philips Acquisition"
description: "Philips acquired BioTelemetry, the leading U.S. provider of remote cardiac monitoring and diagnostics, for $2.8B to create a global leader in patient care management spanning hospital to home."
date: "2021-02-01"
slug: "biotelemetry-philips-2021"
published: true
tags: ["medtech", "remote-monitoring", "cardiac-care", "hospital-to-home", "2021"]
excerpt: "$2.8B acquisition of leading remote cardiac monitoring provider at 6.4x revenue"
readTime: "11 min read"
---

# BioTelemetry -> Philips Acquisition

*Research Completed: 2026-01-03*
*Transaction Status: Closed*

---

## Deal Summary

Philips acquired BioTelemetry, the leading U.S. provider of remote cardiac monitoring and diagnostics, for $2.8 billion in February 2021. This strategic acquisition combined Philips' hospital-based patient monitoring leadership with BioTelemetry's out-of-hospital cardiac monitoring position, creating a global leader in patient care management spanning hospital to home. The deal valued BioTelemetry at approximately 6.4x trailing revenue, reflecting the strategic premium for remote monitoring capabilities during the COVID-19 telehealth boom.

**Key Metrics:**
| Metric | Value | Confidence | Source |
|--------|-------|------------|--------|
| Deal Value (Enterprise) | $2.8B (EUR 2.3B) | High | [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html) |
| Price Per Share | $72.00 | High | [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html) |
| Premium to Market | 16.5% | High | [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html) |
| Target Revenue (2019) | $439M | High | [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html) |
| Revenue Multiple | 6.4x (2019 revenue) | High | [calculated: $2.8B / $439M] |
| Target EBITDA Margin | 26.7% (Q3 2020) | High | [2020-10-29](https://www.gobio.com/news/biotelemetry-inc-reports-third-quarter-2020-financial-results/) |
| EBITDA Multiple | ~24x (estimated) | Medium | [calculated: $2.8B / ~$117M annualized EBITDA] |

---

## Exit Scenario Analysis

**Pattern Identified**: Strategic Medtech Acquisition / Hospital-to-Home Continuum Play

**Why This Classification**:
This deal represents a classic strategic acquisition where a large medtech company (Philips) acquired a complementary capability (out-of-hospital monitoring) to extend its value proposition across the care continuum. The acquisition was driven by the strategic imperative to connect hospital monitoring with home-based remote patient monitoring, accelerated by COVID-19's validation of telehealth and remote care models.

**Evidence**:
- Philips CEO stated deal "fits perfectly with our strategy to be a leading provider of patient care management solutions for the hospital and the home" [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html)
- Philips already monitored 300M hospital patients and 10M home patients; BioTelemetry added 1M+ cardiac patients annually [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html)
- Deal announced during COVID-19 peak when remote monitoring demand surged [2020-12-18](https://www.medtechdive.com/news/philips-buys-BioTelemetry-for-nearly-3-billion/592454/)

**What's Interesting/Unusual About This Deal**:
1. **Relatively modest premium (16.5%)**: Despite strategic importance, Philips secured the deal at reasonable premium
2. **All-cash deal**: $72/share in cash, no stock component
3. **Clear synergy thesis**: Cross-selling, geographic expansion, platform integration
4. **Profitable target**: Unlike many digital health deals, BioTelemetry was profitable (26.7% EBITDA margin)
5. **Services + Technology model**: BioTelemetry combined devices with monitoring services and AI analytics

**Confidence in Classification**: High - Clear strategic rationale with strong source documentation

---

## The Deal

### Transaction Structure
- **Deal Type**: Cash tender offer followed by merger
- **Total Consideration**: $2.8 billion enterprise value
- **Per Share Price**: $72.00 cash
- **Premium**: 16.5% to closing price on December 17, 2020
- **Structure**: All cash, no financing conditions
- **Regulatory**: Hart-Scott-Rodino clearance required

### Deal Timeline
| Date | Event |
|------|-------|
| Dec 18, 2020 | Acquisition announced [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html) |
| Feb 9, 2021 | Tender offer completed [2021-02-09](https://www.philips.com/a-w/about/news/archive/standard/news/press/2021/20210209-philips-completes-the-acquisition-of-biotelemetry-inc.html) |
| Feb 9, 2021 | Transaction closed; BioTelemetry becomes part of Philips Connected Care segment |

### Valuation Analysis
| Metric | Value | Notes |
|--------|-------|-------|
| Enterprise Value | $2.8B | Inclusive of cash and debt |
| 2019 Revenue | $439M | [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html) |
| Q3 2020 Revenue (annualized) | ~$459M | Q3 was $114.7M [2020-10-29](https://www.gobio.com/news/biotelemetry-inc-reports-third-quarter-2020-financial-results/) |
| Revenue Multiple (2019) | 6.4x | |
| Q3 2020 Adj. EBITDA (annualized) | ~$122M | Q3 was $30.6M (26.7% margin) |
| EBITDA Multiple | ~23x | |
| Gross Margin | 60.2% (Q3 2020) | [2020-10-29](https://www.gobio.com/news/biotelemetry-inc-reports-third-quarter-2020-financial-results/) |

---

## Target Company

### What They Did
BioTelemetry was the leading U.S. provider of remote cardiac diagnostics and monitoring services. The company combined wearable heart monitors with AI-based data analytics and clinical services to detect and monitor heart rhythm disorders.

**Core Offerings**:
- **Mobile Cardiac Outpatient Telemetry (MCOT)**: Real-time wireless cardiac monitoring
- **Extended Holter Monitoring**: Longer-duration ECG monitoring via patch devices
- **Remote Patient Monitoring (RPM)**: Chronic condition monitoring services
- **Clinical Research Services**: Core lab services for clinical trials

### Business Model
- **Services + Devices**: Combined proprietary wearable devices with monitoring services
- **Recurring Revenue**: Monitoring services created recurring revenue streams
- **Payer Reimbursement**: Medicare and commercial insurance reimbursement
- **B2B2C**: Sold through physicians who prescribed monitoring for patients

### Scale at Acquisition
- 1+ million cardiac patients monitored annually [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html)
- 30,000+ referring physicians per month [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html)
- ~1,900 employees [2020-12-18](https://www.cnbc.com/2020/12/18/philips-buys-us-cardiac-care-company-biotelemetry-in-2point8-billion-deal.html)
- Headquarters: Malvern, Pennsylvania
- Cardiac monitoring: 85% of revenue

### Financial Performance (Q3 2020)
| Metric | Q3 2020 | Q3 2019 | Change |
|--------|---------|---------|--------|
| Revenue | $114.7M | $111.3M | +3.0% |
| Gross Profit | $69.0M | $69.3M | -0.4% |
| Gross Margin | 60.2% | 62.3% | -210bps |
| Adj. EBITDA | $30.6M | $31.5M | -2.9% |
| EBITDA Margin | 26.7% | 28.3% | -160bps |

Source: [2020-10-29](https://www.gobio.com/news/biotelemetry-inc-reports-third-quarter-2020-financial-results/)

### The "Crown Jewel"
The combination of:
1. **Market leadership**: #1 position in ambulatory cardiac monitoring
2. **Physician network**: 30,000+ referring physicians
3. **AI capabilities**: Proprietary algorithms for arrhythmia detection
4. **Recurring revenue model**: Services-based business with predictable revenue

---

## Acquirer Context

### Who They Are
Royal Philips is a Dutch health technology company focused on improving people's health and well-being. The company is a global leader in diagnostic imaging, image-guided therapy, patient monitoring, and health informatics.

**Key Stats**:
- 2019 Sales: EUR 19.5 billion
- Employees: ~81,000
- Headquarters: Amsterdam, Netherlands
- Listed: NYSE (PHG), Euronext Amsterdam (PHIA)

### Healthcare Strategy
Philips' strategy centers on transforming healthcare delivery across the "health continuum" - from healthy living and prevention, through diagnosis, treatment, and home care. The company had been actively building its Connected Care segment through organic growth and acquisitions.

### Why They Bought This
**Stated Rationale** [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html):
- "Fits perfectly with our strategy to be a leading provider of patient care management solutions for the hospital and the home"
- "BioTelemetry's leadership in ambulatory cardiac diagnostics and monitoring complements our leading position in the hospital"
- Create "global leader in patient care management solutions"

**Value Capture Thesis**:
1. **Cross-selling**: Sell BioTelemetry services to Philips' hospital customers
2. **Geographic expansion**: Extend BioTelemetry's U.S. business globally
3. **Platform synergies**: Integrate with Philips HealthSuite digital platform
4. **Operational improvements**: Apply Philips productivity programs
5. **Innovation synergies**: Combine R&D capabilities

### Prior M&A Pattern
Philips had been actively acquiring to build its connected care portfolio:
- Followed BioTelemetry with Capsule Technologies ($635M, Jan 2021) [2021-01-19](https://www.medtechdive.com/news/philips-buys-capsule-technologies-635m/593551/)
- Subsequently acquired Cardiologs (AI-based ECG analysis, Nov 2021)

---

## Strategic Analysis

### Stated Rationale vs. Probable Reality
| Stated | Probable Reality |
|--------|------------------|
| "Hospital to home" continuum | Defensive play as care shifts out of hospital |
| "Global leader" positioning | Compete with emerging remote monitoring players |
| "Synergies" | Revenue synergies more likely than cost synergies |

### Value Capture Mechanism
1. **Revenue synergies**: Cross-sell BioTelemetry to Philips hospital customers
2. **Geographic expansion**: Take U.S.-centric BioTelemetry global
3. **Platform integration**: Connect to Philips HealthSuite cloud platform
4. **Margin expansion**: Target 20%+ EBITDA margin by 2025 [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html)
5. **Growth acceleration**: Expected "double-digit growth" post-acquisition

### Relevance to Dimer Health
**Medium-High relevance** - This deal demonstrates:
1. **Remote monitoring is valued at premium multiples**: 6.4x revenue for proven remote monitoring business
2. **Profitable model matters**: BioTelemetry's 27% EBITDA margin supported strong valuation
3. **Hospital-to-home thesis**: Strategic buyers pay for capabilities that bridge hospital and home care
4. **AI + Services model**: Combination of technology and clinical services is attractive
5. **Large strategic acquirers**: Medtech companies are active healthcare services acquirers

**Key Differences from Dimer**:
- BioTelemetry focused on cardiac; Dimer focuses on transitional care broadly
- BioTelemetry was $439M revenue, mature business; Dimer is early-stage
- BioTelemetry was device + services; Dimer is primarily virtual services
- BioTelemetry was physician-prescribed; Dimer partners with health systems

---

## Post-Deal Outcomes

- BioTelemetry integrated into Philips Connected Care segment
- Brand maintained as "Philips Ambulatory Monitoring and Diagnostics"
- Philips subsequently faced challenges with product recalls in other divisions
- BioTelemetry paid $14.7M to settle False Claims Act allegations (Dec 2023) [2023-12-20](https://www.massdevice.com/philips-biotelemetry-settle-false-claims/)

---

## Comparable Transactions

| Target | Acquirer | Year | Value | Rev Multiple | Notes |
|--------|----------|------|-------|--------------|-------|
| BioTelemetry | Philips | 2021 | $2.8B | 6.4x | Remote cardiac monitoring |
| Capsule Technologies | Philips | 2021 | $635M | N/A | Hospital device integration |
| Cardiologs | Philips | 2021 | N/A | N/A | AI ECG analysis |
| Livongo | Teladoc | 2020 | $18.5B | ~25x | Remote chronic care (peak valuations) |

---

## Research Notes

### Key Sources
- Philips press release [2020-12-18](https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html)
- Philips acquisition completion [2021-02-09](https://www.philips.com/a-w/about/news/archive/standard/news/press/2021/20210209-philips-completes-the-acquisition-of-biotelemetry-inc.html)
- BioTelemetry Q3 2020 earnings [2020-10-29](https://www.gobio.com/news/biotelemetry-inc-reports-third-quarter-2020-financial-results/)
- CNBC coverage [2020-12-18](https://www.cnbc.com/2020/12/18/philips-buys-us-cardiac-care-company-biotelemetry-in-2point8-billion-deal.html)
- MedTech Dive coverage [2020-12-18](https://www.medtechdive.com/news/philips-buys-BioTelemetry-for-nearly-3-billion/592454/)

### Data Gaps & Limitations
- Full year 2020 revenue not available at acquisition announcement
- Detailed synergy realization not publicly tracked post-close
- Geographic revenue breakdown not disclosed

### Open Questions
- How has BioTelemetry performed within Philips post-acquisition?
- Were the promised synergies realized?
- How did Philips' broader challenges affect BioTelemetry integration?

---

## Tags

`strategic-acquisition` `remote-patient-monitoring` `cardiac-monitoring` `medtech` `profitable-target` `hospital-to-home` `2021` `$1B+`

---

*Research completed: 2026-01-03*
